Exact Sciences Stock Forecast, Price & News

$107.84
-4.07 (-3.64 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$107.01
$113.62
50-Day Range
$106.83
$131.01
52-Week Range
$70.75
$159.54
Volume1.42 million shs
Average Volume1.57 million shs
Market Capitalization$18.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.38
30 days | 90 days | 365 days | Advanced Chart
Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.


Exact Sciences logo

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.51 out of 5 stars

Medical Sector

104th out of 2,220 stocks

Commercial Physical Research Industry

2nd out of 40 stocks

Analyst Opinion: 4.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

Is Exact Sciences a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Exact Sciences?

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for Exact Sciences
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings data on Tuesday, July, 27th. The medical research company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.31. Exact Sciences had a negative net margin of 50.52% and a negative trailing twelve-month return on equity of 8.93%.
View Exact Sciences' earnings history
.

How has Exact Sciences' stock been impacted by Coronavirus (COVID-19)?

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EXAS stock has increased by 86.5% and is now trading at $107.84.
View which stocks have been most impacted by COVID-19
.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences updated its FY 2021 earnings guidance on Wednesday, July, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.71 billion-$1.75 billion, compared to the consensus revenue estimate of $1.72 billion.

What price target have analysts set for EXAS?

16 equities research analysts have issued 12-month price targets for Exact Sciences' stock. Their forecasts range from $120.00 to $180.00. On average, they expect Exact Sciences' stock price to reach $151.06 in the next twelve months. This suggests a possible upside of 40.1% from the stock's current price.
View analysts' price targets for Exact Sciences
or view top-rated stocks among Wall Street analysts.

What are Wall Street analysts saying about Exact Sciences stock?

Here are some recent quotes from research analysts about Exact Sciences stock:
  • 1. According to Zacks Investment Research, "Exact Sciences has outperformed its industry in the past year. Robust top-line growth during the first quarter of 2021, despite the pandemic-led headwinds, is impressive. The contraction in quarterly loss compared to the year-ago period buoys optimism. Revenues from the COVID-19 tests conducted during the quarter contributed to the top line. The company’s legacy Screening business saw an improvement in revenues on Cologuard volume growth. Expansion in gross margin bodes well. Notably, Exact Sciences exited the first quarter with better-than-expected numbers. On the flip side, continued dismal bottom-line performance in the first quarter is discouraging. Contraction in gross margin on escalating costs is worrisome as well. The company’s operating loss in the reported quarter does not bode well either." (7/13/2021)
  • 2. The Goldman Sachs Group, Inc. analysts commented, " (6/3/2021)

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 55, Pay $1.92M)
  • Mr. Jeffrey T. Elliott CFA, Exec. VP, CFO & COO (Age 43, Pay $847.38k)
  • Mr. D. Scott Coward, Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec. (Age 56, Pay $826.6k)
  • Mr. Graham P. Lidgard, Emeritus Chief Science Officer (Age 72, Pay $852.84k)
  • Mr. Jake Orville, Gen. Mang. of Pipeline (Age 47, Pay $651.43k)
  • Mr. Gary Frings, Chief Information Officer
  • Dr. Scott C. Johnson Ph.D., Chief Science Officer and Sr. VP of R&D
  • Ms. Megan Jones, Associate Mang. of Investor Relations
  • Mr. Tim Caprez, Chief Compliance Counsel & VP
  • Mr. Vic Parker, Head of Sales

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Exact Sciences' key competitors?

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Aegon Asset Management UK PLC (0.19%), Moody National Bank Trust Division (0.06%), Alliancebernstein L.P. (0.05%), Heritage Investors Management Corp (0.05%), Zweig DiMenna Associates LLC (0.03%) and EFG Asset Management Americas Corp. (0.02%). Company insiders that own Exact Sciences stock include Canada Pension Plan Investment, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences
.

Which major investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Bradley Mark J., Wisconsin Capital Management LLC, Focused Wealth Management Inc, Patten & Patten Inc. TN, Stratos Wealth Partners LTD., Paradigm Asset Management Co. LLC, and Moody National Bank Trust Division. Company insiders that have sold Exact Sciences company stock in the last year include Canada Pension Plan Investment, Graham Peter Lidgard, Jacob A Orville, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences
or view top insider-selling stocks.

Which major investors are buying Exact Sciences stock?

EXAS stock was bought by a variety of institutional investors in the last quarter, including Aegon Asset Management UK PLC, Zweig DiMenna Associates LLC, Heritage Investors Management Corp, Exchange Traded Concepts LLC, LaFleur & Godfrey LLC, IFM Investors Pty Ltd, Usca Ria LLC, and Advisors Asset Management Inc..
View insider buying and selling activity for Exact Sciences
or or view top insider-buying stocks.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $107.84.

How much money does Exact Sciences make?

Exact Sciences has a market capitalization of $18.54 billion and generates $1.49 billion in revenue each year. The medical research company earns $-848,530,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Exact Sciences have?

Exact Sciences employs 5,000 workers across the globe.

Does Exact Sciences have any subsidiaries?

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

What is Exact Sciences' official website?

The official website for Exact Sciences is www.exactsciences.com.

Where are Exact Sciences' headquarters?

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]


This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.